12.86
Schlusskurs vom Vortag:
$13.44
Offen:
$13.51
24-Stunden-Volumen:
359.66K
Relative Volume:
0.63
Marktkapitalisierung:
$1.38B
Einnahmen:
Nettoeinkommen (Verlust:
KGV:
-
EPS:
-
Netto-Cashflow:
1W Leistung:
-1.83%
1M Leistung:
-19.22%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
Freenome, Inc. Common stock Stock (FRNM) Company Profile
Firmenname
Freenome, Inc. Common stock
Sektor
Branche
Telefon
-
Adresse
-
Compare FRNM vs TMO, DHR, NTRA, A, WAT
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
FRNM
Freenome, Inc. Common stock
|
12.86 | 1.38B | 0 | 0 | 0 | 0.00 |
|
TMO
Thermo Fisher Scientific Inc
|
709.18 | 262.22B | 45.20B | 6.87B | 6.75B | 18.19 |
|
DHR
Danaher Corp
|
236.98 | 166.59B | 24.78B | 3.68B | 5.29B | 5.1743 |
|
NTRA
Natera Inc
|
436.00 | 62.85B | 2.50B | -226.32M | 71.51M | -1.6412 |
|
A
Agilent Technologies Inc
|
181.15 | 51.07B | 7.23B | 1.41B | 1.09B | 4.979 |
|
WAT
Waters Corp
|
480.07 | 47.17B | 3.77B | 449.25M | 240.68M | 7.8556 |
Freenome, Inc. Common stock Stock (FRNM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-08-20 | Eingeleitet | Guggenheim | Buy |
| 2026-08-18 | Eingeleitet | TD Cowen | Buy |
| 2026-08-17 | Eingeleitet | BTIG Research | Buy |
| 2026-08-17 | Eingeleitet | Jefferies | Buy |
| 2026-08-14 | Eingeleitet | Leerink Partners | Outperform |
Freenome, Inc. Common stock Aktie (FRNM) Neueste Nachrichten
abrdn Inc. reports a 0.61% Freenome (FRNM) stake held on behalf of underlying clients. - Stock Titan
Form 4 Freenome Inc For: 20 October By Investing.com - Investing.com South Africa
Form 4 Freenome Inc For: 20 October By Investing.com - Investing.com Nigeria
Freenome, Inc.Common stock (Nasdaq:FRNM) Stock Quote - The Chronicle-Journal
Upcoming & Recent IPO'sIPOs Calendar - Yahoo Finance
IPO Calendar for: - Yahoo! Finance Canada
Upcoming & Recent IPO'sIPOs Calendar - Yahoo Finance
Upcoming & Recent IPO'sIPOs Calendar - Yahoo Finance
Freenome, Inc.Common stock (Nasdaq:FRNM) Stock Quote - FinancialContent
Freenome to Present New Validation Data for Next-Generation CRC Screening Test in Late-Breaking Oral Presentation at ACG 2026 - GlobeNewswire Inc.
An updated blood test detected 18.2% of advanced precancerous growths, versus 13.7% in the earlier study. - Stock Titan
IPO Calendar for: - Yahoo! Finance Canada
Freenome, Inc. Common stock (NASDAQ: FRNM) Share Price, FRNM Stock News, FRNM Share Price & Updates - kalkine.ca
Freenome, Inc. Common stock (NASDAQ: FRNM) Share Price, FRNM Stock News, FRNM Share Price & Updates - kalkine.com.au
Freenome (FRNM) CEO left with 345,976 shares after tax withholding - Stock Titan
Roche group holds 18.7M Freenome (NASDAQ: FRNM) shares - Stock Titan
Freenome Registers Up To 75.2 Million Shares For Sale - Yahoo Finance
Jefferies initiates Freenome stock with buy rating on cancer screening potential - Investing.com Nigeria
Freenome, Inc. (FRNM) insider converts 30,000 Class B shares - Stock Titan
Freenome, Inc. (PCSC) director reports common stock and option stakes - Stock Titan
Freenome, Inc. (FRNM) director Douglas Van Oort details equity stake - Stock Titan
Freenome, Inc. (FRNM) CEO details stock and option positions - Stock Titan
Freenome (Nasdaq:FRNM)Stock Analysis - Simply Wall Street
symbol__ Stock Quote Price and Forecast - CNN
Freenome, Inc. (FRNM) closes SPAC deal, nets $310.3M and new backers - Stock Titan
Total common shares outstanding of Freenome, Inc. – NASDAQ:FRNM - TradingView
Freenome, Inc. Common stock (FRNM) Historical Quotes - Nasdaq
Form 4 Perceptive Capital Solutions Corp For: 22 July - Investing.com
Freenome, Inc.: FRNM Stock Price Quote & News - Robinhood
Wilson Sonsini Advises Freenome on IP Matters Related to Business Combination, Public Company Launch - Wilson Sonsini
Upcoming & Recent IPO'sIPOs Calendar - Yahoo Finance
Upcoming & Recent IPO'sIPOs Calendar - Yahoo Finance
Freenome, Inc. (FRNM) stock price, news, quote and history - Yahoo Finance UK
Freenome (FRNM) Stock Price, News & Analysis - Stock Titan
Freenome Debuts as a Publicly Traded Company Focused on Blood-Based Early Cancer Detection - globenewswire.com
Cancer detection specialist Freenome lists on Nasdaq through special purpose merger - mugglehead.com
Freenome Debuts as a Publicly Traded Company Focused on Blood-Based Early Cancer Detection - BioSpace
Upcoming & Recent IPO'sIPOs Calendar - Yahoo! Finance Canada
Upcoming and recent IPOs – IPOs calendar - Yahoo Finance UK
Upcoming & Recent IPO'sIPOs Calendar - Yahoo Finance
Upcoming & Recent IPO'sIPOs Calendar - Yahoo Finance
Upcoming & Recent IPO'sIPOs Calendar - Yahoo Finance
Cancer test developer Freenome's SPAC backers seek one-year extension to close deal - The Business Journals
Freenome to go public via PCSC SPAC (PCSC): $240M PIPE, $525M pro forma cash - Stock Titan
Freenome and Perceptive Capital Solutions Corp Announce Business Combination Agreement to Create a Publicly Listed Company Transforming Blood-Based Multi-Cancer Detection through an AI/ML-Enabled Multiomics Platform - PR Newswire
Cancer detection firm Freenome to go public via $330 million SPAC deal - STAT
PCSC SEC FilingsPerceptive Capital Solutions Corp 10-K, 10-Q, 8-K Forms - Stock Titan
Perceptive Capital Solutions (PCSC) Stock Price, News & Analysis - Stock Titan
CNS Pharmaceuticals, Inc. Common Stock (CNSP) Historical Quotes - Nasdaq
AXGN Stock Price and Chart — NASDAQ:AXGN - TradingView
Finanzdaten der Freenome, Inc. Common stock-Aktie (FRNM)
Es liegen keine Finanzdaten für Freenome, Inc. Common stock (FRNM) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):